Effects of Time, Dose, and Inversion Time for Acute Myocardial Infarct Size Measurements Based on Magnetic Resonance Imaging-Delayed Contrast Enhancement

Journal of the American College of Cardiology

Volumn 47, Issue 10, 2006, Pages 2027-2033

  Wagner, Anja ^a   Mahrholdt, Heiko ^b   Thomson, Louise ^a   Hager, Stefan ^b   Meinhardt, Gabriel ^b   Rehwald, Wolfgang ^a   Parker, Michele ^a   Shah, Dipan ^c   Sechtem, Udo ^b   Kim, Raymond J ^a   Judd, Robert M ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c Nashville Cardiovascular MRI Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOG; DOSE RESPONSE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HUMAN; MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME;

ADULT; AGED; ANIMALS; CLINICAL PROTOCOLS; CONTRAST MEDIA; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS;

EID: 33646236076     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.01.059     Document Type: Article

References (17)

1. Wu E., Judd R.M., Vargas J.D., Klocke F.J., Bonow R.O., and Kim R.J. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 357 (2001) 21-28
2. Simonetti O.P., Kim R.J., Fieno D.S., et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology 218 (2001) 215-223
3. Wagner A., Mahrholdt H., Holly T.A., et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts. an imaging study. Lancet 361 (2003) 374-379
4. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100 (1999) 1992-2002
5. Fieno D.S., Kim R.J., Chen E.L., Lomasney J.W., Klocke F.J., and Judd R.M. Contrast-enhanced magnetic resonance imaging of myocardium at risk. distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 36 (2000) 1985-1991
6. Petersen S.E., Mohrs O.K., Horstick G., et al. Influence of contrast agent dose and image acquisition timing on the quantitative determination of nonviable myocardial tissue using delayed contrast-enhanced magnetic resonance imaging. J Cardiovasc Magn Reson 6 (2004) 541-548
7. Oshinski J.N., Yang Z., Jones J.R., Mata J.F., and French B.A. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation 104 (2001) 2838-2842
8. Kim R.J., Shah D.J., and Judd R.M. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 5 (2003) 505-514
9. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343 (2000) 1445-1453
10. Bland J.M., and Altman D.G. Comparing methods of measurement. why plotting difference against standard method is misleading. Lancet 346 (1995) 1085-1087
11. Weinmann H.J., Laniado M., and Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16 (1984) 167-172
12. Mahrholdt H., Wagner A., Holly T.A., et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 106 (2002) 2322-2327
13. Gibbons R.J., Miller T.D., and Christian T.F. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi. a measure of the efficacy of therapy in acute myocardial infarction. Circulation 101 (2000) 101-108
14. Gibbons R.J., Valeti U.S., Araoz P.A., and Jaffe A.S. The quantification of infarct size. J Am Coll Cardiol 44 (2004) 1533-1542
15. O'Keefe J.H., Grines C.L., DeWood M.A., et al. Poloxamer-188 as an adjunct to primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 78 (1996) 747-750
16. Mahaffey K.W., Puma J.A., Barbagelata N.A., et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 34 (1999) 1711-1720
17. Schaer G.L., Spaccavento L.J., Browne K.F., et al. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation 94 (1996) 298-307